Wolfgang L. Gross

TL;DR: In patients with generalized vasculitis, the withdrawal of cyclophosphamide and the substitution of azathioprine after remission did not increase the rate of relapse, suggesting the duration of exposure to cycloph phosphamide may be safely reduced.

TL;DR: On the basis of evidence and expert consensus, recommendations have been made for the evaluation, investigation, treatment and monitoring of patients with small and medium vessel vasculitis for use in everyday clinical practice.

TL;DR: This study confirms that the pathogenesis of ANCA-associated vasculitis has a genetic component, shows genetic distinctions between granulomatosis with polyang iitis and microscopic polyangiitis that are associated with ANCA specificity, and suggests that the response against the autoantigen proteinase 3 is a central pathogenic feature ofproteinase 3 ANCA -associated vasulitis.

TL;DR: In this article, the authors compared pulse cyclophosphamide with daily oral cyclophotonitrile (OC) for the treatment of generalized ANCA-associated vasculitis with renal involvement but not immediately life-threatening disease.

TL;DR: The MTX regimen was less effective for induction of remission in patients with extensive disease and pulmonary involvement and was associated with more relapses than the CYC regimen after termination of treatment and the high relapse rates support the practice of continuation of immunosuppressive treatment beyond 12 months.